For example, higher PD-L1 expression on the tumor or immunosuppressive myeloid cells in the tumor microenvironment may correlate with a higher response rate to anti-PD-1/PD-L1 mAb therapy [10]. This evidence concerns the gene CD274 and neoplasm.